Kodiak Sciences announced the enrollment of the first patients in its global Phase 3 ALTO trial for KSI-501 in diabetic macular edema (DME). This trial aims to demonstrate the superiority of KSI-501, a bispecific therapy, over aflibercept, a current standard treatment, potentially offering a new, more effective treatment option for DME patients.
Kodiak Sciences has initiated a crucial Phase 3 trial for KSI-501, a bispecific therapy targeting diabetic macular edema (DME). This is a significant step for the precommercial company, as successful trial results could lead to market approval and substantial revenue. The trial's design to prove superiority over aflibercept (marketed by Regeneron) positions KSI-501 as a potential disruptor in the DME treatment landscape. For Kodiak, this represents a long-term opportunity, but short-term stock movement will likely be driven by investor sentiment around trial progress. Regeneron faces a potential long-term competitive threat to its blockbuster drug Eylea, while other companies with DME treatments like Novartis (Lucentis, Beovu) could also see increased competition.